OncoMatch/Clinical Trials/NCT04689048
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Is NCT04689048 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies 18F fluciclovine for brain metastases, adult.
Treatment: 18F fluciclovine — The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able to detect which patients are responding to radiation therapy. In addition, this study will look at the changes of the treated brain metastases using this imaging agent over time.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Disease stage
Metastatic disease required
Confirmed diagnosis of brain metastases with at least one untreated lesion >2 cm in maximum diameter
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: whole-brain radiation therapy
Prior whole-brain radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Miami Cancer Institute · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04689048 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior whole-brain radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages